Glioblastoma trial of intra-arterial cetuximab is recruiting at Northwell Health
A Northwell Health registry entry shows a PHASE1, PHASE2 glioblastoma study recruiting, with primary outcomes focused on 6-month progression-free survival and 2-year overall survival.
A Northwell Health study on newly diagnosed glioblastoma is recruiting now, and that matters because the trial is testing a treatment approach that goes directly into the artery. The registry entry says the study is in PHASE1, PHASE2 and lists its overall status as RECRUITING.
The study title is Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma. Its primary completion date is estimated for 2028-12, so this is an ongoing study rather than a finished one.
"This record describes a study and its registry status; study outcomes require posted results." — ctgov_v2
What the trial is testing
The registry lists two interventions in the same experimental arm: Intra-arterial Cetuximab and Intra-arterial Mannitol. The arm group is labeled Intra-arterial Cetuximab after BBBD, which is the exact study label used in the entry.
For readers, the main point is simple: the study is examining whether this drug delivery approach can be used in people with newly diagnosed glioblastoma. Because the record has no results, it does not show whether the approach works; it only shows that the study is open to enrollment.
"The 6-month PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free." — ctgov_v2
How the study will be measured
The primary outcomes are Progression Free Survival (PFS) at 6 months and Overall Survival (OS) at 2 years. Progression-free survival means the time a patient lives without the cancer getting worse, while overall survival tracks time from treatment start until death.
Those endpoints tell readers what the study hopes to measure over time, but they are not outcomes yet. The registry does not provide posted results, so the most current fact is simply that the trial is recruiting and that its main readouts are still ahead.
"OS will be calculated as the time from treatment initiation to the date of death." — ctgov_v2
Why it fits the wider cancer research picture
This study appears in the active Cancer Breakthroughs special event, alongside other recruiting or not-yet-recruiting cancer studies. That shared setting suggests ongoing interest in new ways to study cancer treatment, including trials that pair drugs with local therapy.
One related internal article in the same event tracks Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients, which shows how broad cancer-related research can be. The glioblastoma study stands apart as a brain cancer trial, but it belongs to the same live stream of oncology registry activity.
"Registry observation: Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma (PHASE1, PHASE2, RECRUITING)." — ctgov_v2